What do systematic reviews say?

Febuxostat 40 mg/day vs placebo

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 40 mg/day vs placebo

Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1 [0, 0]
  1 study · 75 participants
  Moderate

Febuxostat 40 mg/day vs placebo

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1 [0.07, 15.8]
  1 study · 75 participants
  Moderate

Febuxostat 80 mg/day vs placebo

Febuxostat 80 mg/day showed no clear difference in incidence of gout flares compared with placebo (low certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.32 [0.96, 1.8]
  2 studies · 474 participants
  Low

Febuxostat 80 mg/day vs placebo

Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 68.9 [13.8, 343.9]
  2 studies · 332 participants
  Low

Febuxostat 120 mg/day vs placebo

Febuxostat 120 mg/day probably leads to higher incidence of gout flares compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.7 [1.3, 2.3]
  2 studies · 479 participants
  Moderate

Febuxostat 120 mg/day vs placebo

Febuxostat 120 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 80.7 [16, 405.5]
  2 studies · 356 participants
  Low

Febuxostat 120 mg/day vs placebo

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 120 mg/day vs placebo

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 120 mg/day vs placebo

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 120 mg/day vs placebo

Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 2.7 [0.7, 10.2]
  2 studies · 479 participants
  Moderate

Febuxostat 120 mg/day vs placebo

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.7 [0.67, 4.1]
  2 studies · 479 participants
  Moderate

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.3 [0.87, 1.9]
  2 studies · 986 participants
  High

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 2.2 [1.9, 2.5]
  2 studies · 880 participants
  Moderate

Febuxostat 120 mg/day vs allopurinol

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 120 mg/day vs allopurinol

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 120 mg/day vs allopurinol

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.2 [0.7, 1.93]
  3 studies · 1041 participants
  High

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.6 [0.49, 5]
  3 studies · 1041 participants
  High

Xylitol candy (7.5 g/day) vs Control (sorbitol) candy

• Xylitol‐containing products for preventing dental caries in children and adults 2015 · Cochrane All outcomes

  36 months
  The authors reported that there were no adverse effects for either group. Honkala 2014.
  1 study · 252 participants
  GRADE not reported